secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001104659-23-112759
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS receives FDA Fast Track for SLS009 in PTCL; raises $4M via registered direct offering
--------------------------------------------------------------------------------

- FDA granted Fast Track Designation for SLS009 to treat relapsed/refractory Peripheral T-cell Lymphomas (PTCL).
- SLS009 showed 36.4% overall response rate in Phase 1 PTCL patients vs 25.8% for standard of care belinostat.
- Registered direct offering of 3,652,300 shares/warrants at $1.0952/share for ~$4M gross proceeds; closing expected Nov 2, 2023.
- Existing warrants from April 2022 repriced to $0.9702 and extended to November 2, 2028.
- A.G.P./Alliance Global Partners acting as lead placement agent; Maxim Group as co-placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465923112759/0001104659-23-112759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465923112759/tm2329480d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-112759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer